Novo Nordisk (NYSE: NVO) shares surged 10% in premarket trading after the FDA fast-tracked its obesity drug Amycretin, which demonstrated a 15% average body weight reduction in Phase 2 trials. The accelerated approval pathway positions the drug for a late-2026 launch, potentially capturing a slice of the $100 billion global obesity treatment market amid soaring demand for GLP-1 alternatives.
Trial Highlights:
-
Efficacy: 88% of patients achieved >10% weight loss.
-
Safety: Mild side effects vs. competitors’ gastrointestinal issues.
-
Market Potential: Targets 1.2 billion obese adults worldwide.
Analyst Commentary:
“Amycretin is positioned to revolutionize the obesity treatment landscape,” asserted JPMorgan healthcare analyst Richard Vosser, “with potential to capture a dominant share of the $100 billion global market.”.
